Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Enliven Therapeutics, Inc. ELVN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
44/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$43.33
-1.4%

Enliven Therapeutics, Inc. (ELVN) is a Biotechnology company in the Healthcare sector, currently trading at $43.95. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ELVN = $43 (-1.4% upside).

Valuation: ELVN trades at a trailing Price-to-Earnings (P/E) of -23.9 (S&P 500 average ~25).

Net income is $104M (loss), growing at -43.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $399,000 against $460M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 28.66 (strong liquidity). Debt-to-assets is 0.1%. Total assets: $476M.

Analyst outlook: 6 / 6 analysts rate ELVN as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 74/100 (Pass), Income ?/100 (Fail).

$43.33
▼ 1.41% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Enliven Therapeutics, Inc., the average price target is $43.33, with a high forecast of $52.00, and a low forecast of $39.00.
Highest Price Target
$52.00
Average Price Target
$43.33
Lowest Price Target
$39.00

ELVN SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 35/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 74/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ELVN

✗
VALUE Fail
35/100
ELVN trades at a trailing Price-to-Earnings (P/E) of -23.9 (S&P 500 average ~25). Forward PEG -0.81 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $43, implying -2.2% from the current price $44. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ELVN: +0%/yr revenue is, -43.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ELVN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 28.66 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
ELVN: Gross margin is 0% (+0 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
74/100
Analyst outlook: 6 / 6 analysts rate ELVN as buy (100%). Analyst consensus target is $43 (-2.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range13.3-40.62
Volume862.58K
Avg Volume (30D)1.16M
Market Cap$2.63B
Beta (1Y)0.49
Share Statistics
EPS (TTM)-1.83
Shares Outstanding$56.66M
IPO Date2020-03-12
Employees62
CEORichard A. Fair
Financial Highlights & Ratios
Gross Profit$-263K
EBITDA$-119.4M
Net Income$-103.69M
Operating Income$-119.66M
Total Cash$462.62M
Total Debt$399K
Net Debt$-98.5M
Total Assets$476.17M
Price / Earnings (P/E)-24
Analyst Forecast
1Y Price Target$39.00
Target High$52.00
Target Low$39.00
Upside-11.3%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS29337E1029

Price Chart

Track all markets on TradingView
ELVN
Enliven Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
13.30 52WK RANGE 40.62

People Also View

CELC
CELC
Celcuity Inc.
$123.47
+2.17%
 GPCR
GPCR
Structure Therapeutics Inc.
$54.25
+1.94%
 MLTX
MLTX
MoonLake Immunotherapeutics
$18.02
-4.05%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.60
+0.49%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.95
+4.18%
 CMPX
CMPX
Compass Therapeutics, Inc.
$5.85
+7.54%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 NVCT
NVCT
Nuvectis Pharma, Inc.
$8.50
-2.63%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message